NBIX Neurocrine Biosciences Inc

Price (delayed)

$134.07

Market cap

$13.49B

P/E Ratio

35.56

Dividend/share

N/A

EPS

$3.77

Enterprise value

$13.61B

Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological ...

Highlights
The price to earnings (P/E) is 76% lower than the 5-year quarterly average of 146.3 and 28% lower than the last 4 quarters average of 49.2
The company's net income rose by 48% QoQ
Neurocrine Biosciences's quick ratio has decreased by 32% YoY but it has increased by 3.6% from the previous quarter
The debt has soared by 97% YoY and by 19% QoQ

Key stats

What are the main financial stats of NBIX
Market
Shares outstanding
100.64M
Market cap
$13.49B
Enterprise value
$13.61B
Valuations
Price to book (P/B)
5.59
Price to sales (P/S)
6.75
EV/EBIT
28.68
EV/EBITDA
27.38
EV/Sales
6.87
Earnings
Revenue
$1.98B
EBIT
$474.5M
EBITDA
$497M
Free cash flow
$614.4M
Per share
EPS
$3.77
Free cash flow per share
$6.16
Book value per share
$23.98
Revenue per share
$19.86
TBVPS
$34.45
Balance sheet
Total assets
$3.47B
Total liabilities
$1.09B
Debt
$511.9M
Equity
$2.39B
Working capital
$1.09B
Liquidity
Debt to equity
0.21
Current ratio
2.52
Quick ratio
2.33
Net debt/EBITDA
0.23
Margins
EBITDA margin
25.1%
Gross margin
98%
Net margin
18.7%
Operating margin
23.4%
Efficiency
Return on assets
12.1%
Return on equity
17.5%
Return on invested capital
19.5%
Return on capital employed
17.2%
Return on sales
23.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBIX stock price

How has the Neurocrine Biosciences stock price performed over time
Intraday
2.45%
1 week
-1.61%
1 month
-5.35%
1 year
38.23%
YTD
1.75%
QTD
-2.79%

Financial performance

How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$1.98B
Gross profit
$1.94B
Operating income
$464.4M
Net income
$369.7M
Gross margin
98%
Net margin
18.7%
The operating margin has soared by 185% YoY and by 76% from the previous quarter
The operating income has surged by 85% since the previous quarter
The company's net income rose by 48% QoQ
The net margin is up by 42% QoQ

Growth

What is Neurocrine Biosciences's growth rate over time

Valuation

What is Neurocrine Biosciences stock price valuation
P/E
35.56
P/B
5.59
P/S
6.75
EV/EBIT
28.68
EV/EBITDA
27.38
EV/Sales
6.87
The price to earnings (P/E) is 76% lower than the 5-year quarterly average of 146.3 and 28% lower than the last 4 quarters average of 49.2
NBIX's EPS is up by 47% since the previous quarter
The company's equity rose by 42% YoY and by 7% QoQ
NBIX's price to book (P/B) is 35% lower than its 5-year quarterly average of 8.6
Neurocrine Biosciences's revenue has increased by 24% YoY and by 5% QoQ
The stock's price to sales (P/S) is 21% less than its 5-year quarterly average of 8.5 but 5% more than its last 4 quarters average of 6.4

Efficiency

How efficient is Neurocrine Biosciences business performance
The ROE has grown by 36% from the previous quarter
Neurocrine Biosciences's return on assets has increased by 34% QoQ
NBIX's return on sales is up by 34% since the previous quarter
The company's return on invested capital rose by 31% QoQ

Dividends

What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBIX.

Financial health

How did Neurocrine Biosciences financials performed over time
The total liabilities has soared by 61% YoY and by 7% from the previous quarter
NBIX's total assets is up by 47% YoY and by 7% from the previous quarter
The debt is 79% lower than the equity
The debt has soared by 97% YoY and by 19% QoQ
The company's equity rose by 42% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.